Ignacio Handal is currently CEO at Clinicom Healthcare. Ignacio has completed a myriad FDA phase I, II, & III studies in pharmaceuticals, and devices over two decades. Ignacio has completed more clinical research studies than 99.8% of all clinical researchers internationally per globaldata.com. Mr Handal has completed clinical studies that have help put 83 plus drugs and devices to market over the last twenty years, These products have touched the lives of over a two hundred million patients. In 2022 Ignacio was honored with the Christine Pierre Clinical trials Europe lifetime achievement award for clinical trials. Only 8 researchers globally have ever been awarded this honor to date. Mr. Handal has led the creation and development of two nationally recognized US clinical research centers, Harmonex Neuroscience Research and Trinity Research at Eye Center South. Harmonex Neuroscience is the clinical research institute that gave birth to Clinicom at its inception, Prior to Clinicom, Ignacio was Director of Clinical Project Management (10/2018-3/2020) and Director of Program Management (8/2018-2/2020) at Biorasi a global CRO. He was Director of Clinical Research at Eye Center South the Third largest surgical center in the USA from 2015-8/2018 where he founded their research division.
Early in his career Ignacio, Co-Founded the 5th leading private CNS research site in the US called Harmonex Neuroscience research in 2003 that continues to this day.
Ignacio and his team have used the profits of their research trials over the years to develop the world’s first online mental health assessment software that can assess anyone remotely for 81 mental health conditions in one virtual assessment. Clinicom has helped accelerate enrollment and patient identification for precise inclusion and exclusion criteria in 70 phase II and III studies in the US. Ignacio and his team have invested over 10 million dollars from their clinical trials work to bring equity and access to mental health in 6 continents.